Laboratory variables and stratification of non resected, non small-cell lung cancer patients: Recommendations for future trials;Variables biologiques et stratification des patients atteints de cancer bronchique non à petites cellules non opérés: Recommandations pour de futurs essais

Cancer/Radiotherapie

Volumn 6, Issue 4, 2002, Pages 209-216

  Watine, J ^a   Friedberg, B ^b   Bouarioua, N ^a  

^a Centre Hospitalier Général   (France)

^b Laboratoire de Biologie Polyvalente   (France)

Author keywords

Laboratory variables; Non small cell lung cancer; Prognosis; Survival

Indexed keywords

CALCIUM; CYTOKERATIN 19 FRAGMENT; HEMOGLOBIN; LACTATE DEHYDROGENASE; TUMOR MARKER;

ACCURACY; ARTICLE; CLINICAL PRACTICE; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; STANDARDIZATION;

EID: 0036343074     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(02)00197-X     Document Type: Article

References (35)

1. Pre-treatment evaluation of non-small-cell lung cancer
2. Bronchogenic carcinoma
3. Regression models and life-tables
4. Radiation myelitis and survival in the radiotherapy of lung cancer
5. Reducing unnecessary laboratory use with new test request form: Example of tumour markers
6. The future of prognostic factors in outcome prediction for patients with cancer
7. Tumor markers in patients with chronic renal failure
8. A randomized trial in inoperable non-small cell lung cancer. Vindesine and cisplatin versus mitomycin, vindesine and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin
9. Continuing controversies in staging NSCLC: An analysis of the revised 1997 staging system
10. Preanalytical factors and their influence on analytical quality specifications
11. Survival predictors in advanced non-small cell lung cancer
12. Training and practice in evidence based laboratory medicine
13. Prognostic factors in advanced non-small cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis
14. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials
15. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy
16. Prognostic factors for survival in inoperable non-small cell lung cancer: A multivariate regression analysis of 456 patients with radiation therapy
17. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1 052 patients
18. Cyfra 21-1 neuron specific enolase and prognosis of non-small cell lung cancer: Prospective study in 621 patients
19. Serum Cyfra 21-1 as a co-variable in future NSCLC chemotherapy trials
20. Systematic reviewing in laboratory medicine. Position paper from the IFCC committee on systematic reviewing in laboratory medicine
21. A prognostic-factor risk index in advanced non-small cell lung cancer treated with cisplatin-containing combination chemotherapy
22. Recommandations concernant l'utilisation des marqueurs tumoraux sériques dans la prise en charge des cancers bronchiques primitifs
23. Prognostic factors in inoperable adenocarcinoma of the lung: A multivariate regression analysis of 259 patients
24. Prognostic value of pleural effusion in patients with non-small cell lung cancer
25. Prognostic factors for patients with advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation
26. Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer
27. Le défaut d'expertise biologique de certaines publications médicales
28. Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review
29. Prognostic value of hypercoagulability in cancer patients
30. Comments on: Anemia as an independent prognostic factor for survival in patients with cancer
31. Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival
32. A practical prognostic index for inoperable non-small cell lung cancer
33. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer
34. Überlebenszeiten ausschließlich bestrahlter patienten. Die bedeutung des prätherapeutischen hämoglobinwerts